MedInCell Stock Drops 20% in Three Months, Approaching Oversold Territory
MedInCell shares fell 2.48% at the opening of the session this Thursday, March 19, trading at 20.46 euros in a declining Parisian market. The CAC 40 is down 1.64% during the session, while the SBF 120 drops 1.65%. The Montpellier-based biotech now shows a decline of over 20% over three months.
MedInCell's share price is significantly below its main moving averages: the 50-day moving average at 24.30 euros, and the 200-day moving average at 23.20 euros, indicating a bearish trajectory established over several weeks. The increasing gap between the current price and these trend indicators highlights the magnitude of the recent correction, with the stock having lost 7.25% over the last seven days. The RSI, a momentum indicator that measures the speed and change of price movements, is at 35, close to the oversold zone (below 30), signaling that selling pressure remains dominant. The nearest support threshold is at 20.34 euros: a break below this level could intensify the downward movement. At this stage, the stock is oscillating near the lower Bollinger band (19.84 euros), an area that usually corresponds to a short-term excess weakness.
Yearly Growth Amid Recent Declines
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Despite the decline over the past three months, MedInCell stock still shows a gain of 41.69% over the year, driven by the company's advancements in the field of extended-release drug delivery technologies. The stock's beta, at 0.17, indicates a low correlation with general market movements: the recent decline does not seem solely attributable to the downturn in European indices. The next major event is scheduled for June 16, 2026, the date of the annual results publication for the fiscal year 2025-2026. This deadline will be followed by the general meeting on September 10, and the results for the first half of 2026-2027 on December 8. These milestones will provide the market with opportunities to assess the company's operational and financial trajectory, as the monthly volatility of the stock stands at 15.77%.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
